Ga 3 + can be introduced into receptor-specific peptidic carriers via different chelators to obtain radiotracers for Positron Emission Tomography imaging and the chosen chelating agent considerably influences the in vivo pharmacokinetics of the corresponding radiopeptides. A chelator that should be a valuable alternative to established chelating agents for 68 Garadiolabeling of peptides would be a backbone-functionalized variant of the chelator CB-DO2A. Here, the bifunctional crossbridged chelating agent CB-DO2A-GA was developed and compared to the established chelators DOTA, NODA-GA and DOTA-GA. For this purpose, CB-DO2A-GA(tBu) 2 was introduced into the peptide Tyr 3 -octreotate (TATE) and in direct comparison to the corresponding DOTA-, NODA-GA-, and DOTA-GA-modi-fied TATE analogs, CB-DO2A-GA-TATE required harsher reaction conditions for 68 Ga-incorporation. Regarding the hydrophilicity profile of the resulting radiopeptides, a decrease in hydrophilicity from [ 68 Ga]Ga-DOTA-GA-TATE (log D(7.4) of À 4.11 � 0.11) to [ 68 Ga]Ga-CB-DO2A-GA-TATE (À 3.02 � 0.08) was observed. Assessing the stability against metabolic degradation and complex challenge, [ 68 Ga]Ga-CB-DO2A-GA demonstrated a very high kinetic inertness, exceeding that of [ 68 Ga]Ga-DOTA-GA. Therefore, CB-DO2A-GA is a valuable alternative to established chelating agents for 68 Ga-radiolabeling of peptides, especially when the formation of a very stable, positively charged 68 Gacomplex is pursued.